ClinicalTrials.gg
CompletedNCT01354717Updated Oct 20, 2014

Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo

A Phase 3 interventional study of Brand Carac and Generic 0.5% 5-fluorouracil cream in Actinic Keratoses, sponsored by Spear Pharmaceuticals. Completed. Open to participants aged 45 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-20.

Sponsored by Spear Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing fluorouracil in Keratosis, Actinic — 3 open to participants now, 5 under way, 1 of them phase 3. Fluorouracil · Keratosis, Actinic.

Enrollment
5th of 19
377 · median 60
Started
2010
with 1 other
Phase 3
9 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
1 of 19
Spear Pharmaceuticals

Among the 19 studies testing fluorouracil in Keratosis, Actinic, this one is the 5th largest by enrollment, is one of 2 that started in 2010, is one of 9 in phase 3, and was the 4th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

3 of the 19 studies testing fluorouracil in Keratosis, Actinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing fluorouracil in Keratosis, Actinic, or all of them as a file.
02

Study summary

This is a double-blind, randomized, placebo-controlled, three treatment parallel study in which normal, healthy men and women (age 45-85) with actinic keratosis will be treated on the face once daily for two weeks with 5-Fluorouracil Cream 0.5%, Spear Pharmaceuticals (Generic), Carac® Cream 0.5% (Brand), or Cream Vehicle (Placebo). Actinic keratoses will be counted at the baseline visit and at the visit four weeks following cessation of treatment.

Read the detailed description

actinic keratosis

03

Conditions studied

  • Actinic Keratoses

Browse trials for

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Men and women with the presence of actinic keratoses

  • Women who have had surgical sterilization or are (absence of menses for at least one year) are eligible. Women of who are non-pregnant and non-nursing, and willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study are eligible. (Adequate is defined as regular use of, diaphragm with condoms, IUD with condoms, or systemic contraceptives - if used for at least three months prior to enrollment in the study). A negative pregnancy test is required at entry into the study
  • Able to refrain from the use of all other topical medications to the facial area during the treatment period
  • Considered reliable and capable of understanding their responsibility and role in the study
  • Have provided written

Exclusion criteria

Exclusion Criteria:

  • History of allergy or to 5-fluorouracil

    • Known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
    • Clinical evidence of severe, uncontrolled auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, pulmonary or renal disease
    • Dermatologic conditions if present on the face such as: atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, or albinism
    • Positive urine pregnancy test in women of
    • Inability to use adequate measures for women of child-bearing potential, as defined above
    • Serious psychological illness
    • Significant history (within the past year) of alcohol or drug abuse
    • Participation in any clinical research study during the 30 day period preceding study initiation
    • Medical history which, based on the clinical judgment of the investigator, implies an unlikelihood of successful completion of the study
    • Treatment for actinic keratosis or skin cancer in the previous 28 days with the following: topical 5 fluorouracil, cryodestruction (liquid nitrogen spray), curettage (scraping of pre-cancer or skin cancers), surgical removal of skin cancer, photodynamic therapy, surgical excision, topical diclofenac (Solaraze), topical imiquimod (Aldara), topical retinoids if used for actinic keratosis or other treatments for actinic keratoses
    • Application of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (psoralen plus ultraviolet A) therapy, or 5) UVB therapy to the face or bald scalp within six months prior to randomization
    • Use of sun lamps or sun tanning beds or booths during the 2 weeks prior to first application until Day 42 visit
    • Any oral (systemic ) or topical corticosteroids within 1 month of study entry, except for subjects on chronic low dose corticosteroids less than 5 mg daily for greater than 1 year
    • Use within 1 month of any immunomodulators like interferon, or cytotoxic drugs
    • Prior treatment with systemic 5-fluorouracil or systemic cancer therapy within 6 months of study entry
    • Subjects with lesions suspicious for squamous cell carcinoma
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
377 participants (actual)

Study arms

  • Active comparator
    Brand Carac

    Treatment of actinic keratosis with active ingredient

    Drug: Brand Carac

  • Active comparator
    Generic 0.5% 5-fluorouracil cream

    Treatment of actinic keratosis with active ingredient

    Drug: Generic 0.5% 5-fluorouracil cream

  • Placebo comparator
    Placebo

    treatment of actinic keratosis with placebo cream

    Other: Placebo cream

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of patients with clearing

    Time frame: August 28, 2010 to March 17, 2011

  2. Clearing of actinic keratosis

    Time frame: 42 days

Secondary outcomes

  1. superiority to placebo

    Time frame: 42 days

Other outcomes

  1. Irritation

    Time frame: 14 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2011
First posted
May 17, 2011
Start
Sep 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results delay requested
Sep 7, 2014
Last update
Oct 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01354717
Lead sponsor
Spear Pharmaceuticals
Responsible party
Sponsor
First posted
May 17, 2011
Start date
Sep 2010
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Oct 20, 2014

Study contacts

Melanie Appell, M.D.
principal investigator · Alliance Clinical Research, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Generic Drug

Start the discussion